Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4288-4298

  Marcon, Rodrigo ^a,b   Bento, Allisson F ^a,b   Dutra, Rafael C ^a   Bicca, Maira A ^a,b   Leite, Daniela F P ^a,b   Calixto, João B ^a,b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Center of Innovation and Preclinical Studies CIEnP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MARESIN 1; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; GENE EXPRESSION; ICAM 1 GENE; INHIBITION KINETICS; MACROPHAGE; MALE; MANNOSE RECEPTOR C TYPE 1 GENE; MARKER GENE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; COLITIS; COLON; DEXTRAN SULFATE; DOCOSAHEXAENOIC ACIDS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; NEUTROPHILS; NF-KAPPA B; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885465373     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202743     Document Type: Article

References (75)

1. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197.
2. Serhan, C. N., S. D. Brain, C. D. Buckley, D. W. Gilroy, C. Haslett, L. A. O'Neill, M. Perretti, A. G. Rossi, and J. L. Wallace. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21: 325-332.
3. Willoughby, D. A., A. R. Moore, P. R. Colville-Nash, and D. Gilroy. 2000. Resolution of inflammation. Int. J. Immunopharmacol. 22: 1131-1135.
4. Serhan, C. N., S. Yacoubian, and R. Yang. 2008. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 3: 279-312.
5. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R. L. Moussignac. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037.
6. Nathan, C. 2002. Points of control in inflammation. Nature 420: 846-852.
7. Fadok, V. A., D. L. Bratton, A. Konowal, P. W. Freed, J. Y. Westcott, and P. M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-b, PGE2, and PAF. J. Clin. Invest. 101: 890-898.
8. Russo, G. L. 2009. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem. Pharmacol. 77: 937-946.
9. Serhan, C. N., K. Gotlinger, S. Hong, and M. Arita. 2004. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirintriggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 73: 155-172.
10. Serhan, C. N., T. Takano, N. Chiang, K. Gronert, and C. B. Clish. 2000. Formation of endogenous "antiinflammatory" lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability. Am. J. Respir. Crit. Care Med. 161: S95-S101.
11. Serhan, C. N., R. Yang, K. Martinod, K. Kasuga, P. S. Pillai, T. F. Porter, S. F. Oh, and M. Spite. 2009. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206: 15-23.
12. Dalli, J., M. Zhu, N. A. Vlasenko, B. Deng, J. Z. Haeggstrom, N. A. Petasis, and C. N. Serhan. 2013. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 27: 2573-2583.
13. Nordgren, T. M., A. J. Heires, T. A. Wyatt, J. A. Poole, T. D. Levan D. R. Cerutis, and D. J. Romberger. 2013. Maresin-1 reduces the proinflammatory response of bronchial epithelial cells to organic dust. Respir. Res. 14: 51.
14. Serhan, C. N., J. Dalli, S. Karamnov, A. Choi, C. K. Park, Z. Z. Xu, R. R. Ji, M. Zhu, and N. A. Petasis. 2012. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26: 1755-1765.
15. Maloy, K. J., and F. Powrie. 2011. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474: 298-306.
16. Hooper, L. V., and A. J. Macpherson. 2010. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 10: 159-169.
17. Baumgart, D. C., and S. R. Carding. 2007. Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.
18. Molodecky, N. A., I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I. Benchimol, R. Panaccione, S. Ghosh, H. W. Barkema, and G. G. Kaplan. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46-54.e42.
19. Bento, A. F., R. F. Claudino, R. C. Dutra, R. Marcon, and J. B. Calixto. 2011. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J. Immunol. 187: 1957-1969.
20. Ishida, T., M. Yoshida, M. Arita, Y. Nishitani, S. Nishiumi, A. Masuda, S. Mizuno, T. Takagawa, Y. Morita, H. Kutsumi, et al. 2010. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 16: 87-95.
21. Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102: 7671-7676.
22. Bento, A. F., D. F. Leite, R. Marcon, R. F. Claudino, R. C. Dutra, M. Cola, A. C. Martini, and J. B. Calixto. 2012. Evaluation of chemical mediators and cellular response during acute and chronic gut inflammatory response induced by dextran sodium sulfate in mice. Biochem. Pharmacol. 84: 1459-1469.
23. Ghia, J. E., P. Blennerhassett, and S. M. Collins. 2008. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J. Clin. Invest. 118: 2209-2218.
24. Kimball, E. S., N. H.Wallace, C. R. Schneider, M. R. D'Andrea, and P. J. Hornby. 2004. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol. Motil. 16: 811-818.
25. Wallace, J. L., W. K. MacNaughton, G. P. Morris, and P. L. Beck. 1989. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96: 29-36.
26. Dutra, R. C., R. F. Claudino, A. F. Bento, R. Marcon, E. C. Schmidt, Z. L. Bouzon, L. F. Pianowski, and J. B. Calixto. 2011. Preventive and therapeutic euphol treatment attenuates experimental colitis in mice. PLoS ONE 6: e27122.
27. Neurath, M. F., I. Fuss, B. L. Kelsall, E. Stüber, andW. Strober. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281-1290.
28. Bento, A. F., D. F. Leite, R. F. Claudino, D. B. Hara, P. C. Leal, and J. B. Calixto. 2008. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J. Leukoc. Biol. 84: 1213-1221.
29. Cowland, J. B., and N. Borregaard. 1999. Isolation of neutrophil precursors from bone marrow for biochemical and transcriptional analysis. J. Immunol. Methods 232: 191-200.
30. Rao, K. M., J. Padmanabhan, D. L. Kilby, H. J. Cohen, M. S. Currie, and J. B. Weinberg. 1992. Flow cytometric analysis of nitric oxide production in human neutrophils using dichlorofluorescein diacetate in the presence of a calmodulin inhibitor. J. Leukoc. Biol. 51: 496-500.
31. Gomes, A., E. Fernandes, and J. L. Lima. 2005. Fluorescence probes used for detection of reactive oxygen species. J. Biochem. Biophys. Methods 65: 45-80.
32. Stanley, E. R. 1997. Murine bone marrow-derived macrophages. Methods Mol. Biol. 75: 301-304.
33. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
34. Stevceva, L., P. Pavli, A. J. Husband, and W. F. Doe. 2001. The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin. Pathol. 1: 3.
35. Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652.
36. Abraham, C., and J. H. Cho. 2009. Inflammatory bowel disease. N. Engl. J. Med. 361: 2066-2078.
37. Ledeboer, A., M. Gamanos, W. Lai, D. Martin, S. F. Maier, L. R. Watkins, and N. Quan. 2005. Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur. J. Neurosci. 22: 1977-1986.
38. Neurath, M. F., and S. Pettersson. 1997. Predominant role of NF-kB p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology 198: 91-98.
39. Sans, M., J. Panés, E. Ardite, J. I. Elizalde, Y. Arce, M. Elena, A. Palacín, J. C. Fernández-Checa, D. C. Anderson, R. Lobb, and J. M. Piqué. 1999. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 116: 874-883.
40. Kolaczkowska, E., and P. Kubes. 2013. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13: 159-175.
41. Fournier, B. M., and C. A. Parkos. 2012. The role of neutrophils during intestinal inflammation. Mucosal Immunol. 5: 354-366.
42. Amulic, B., C. Cazalet, G. L. Hayes, K. D. Metzler, and A. Zychlinsky. 2012. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30: 459-489.
43. Farooq, S. M., R. Stillie, M. Svensson, C. Svanborg, R. M. Strieter, and A. W. Stadnyk. 2009. Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J. Pharmacol. Exp. Ther. 329: 123-129.
44. Geering, B., C. Stoeckle, S. Conus, and H. U. Simon. 2013. Living and dying for inflammation: neutrophils, eosinophils, basophils. Trends Immunol. 34: 398-409.
45. Arruda, M. A., and C. Barja-Fidalgo. 2009. NADPH oxidase activity: In the crossroad of neutrophil life and death. Front. Biosci. (Landmark Ed.) 14: 4546-4556.
46. Tabas, I. 2010. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10: 36-46.
47. Shalhoub, J., M. A. Falck-Hansen, A. H. Davies, and C. Monaco. 2011. Innate immunity and monocyte-macrophage activation in atherosclerosis. J. Inflamm. (Lond.) 8: 9.
48. Berndt, B. E., M. Zhang, G. H. Chen, G. B. Huffnagle, and J. Y. Kao. 2007. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J. Immunol. 179: 6255-6262.
49. Ferretti, M., V. Casini-Raggi, T. T. Pizarro, S. P. Eisenberg, C. C. Nast, and F. Cominelli. 1994. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J. Clin. Invest. 94: 449-453.
50. Martinez, F. O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177: 7303-7311.
51. Hara, D. B., E. S. Fernandes, M. M. Campos, and J. B. Calixto. 2007. Pharmacological and biochemical characterization of bradykinin B2 receptors in the mouse colon: influence of the TNBS-induced colitis. Regul. Pept. 141: 25-34.
52. Cabré, E., M. Mañosa, and M. A. Gassull. 2012. Omega-3 fatty acids and inflammatory bowel diseases: a systematic review. Br. J. Nutr. 107(Suppl. 2): S240-S252.
53. Cho, J. Y., S. G. Chi, and H. S. Chun. 2011. Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol. Nutr. Food Res. 55: 239-246.
54. Connor, W. E., and S. L. Connor. 2007. The importance of fish and docosahexaenoic acid in Alzheimer disease. Am. J. Clin. Nutr. 85: 929-930.
55. Kinsella, J. E., B. Lokesh, and R. A. Stone. 1990. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. Am. J. Clin. Nutr. 52: 1-28.
56. Cole, G. M., and S. A. Frautschy. 2006. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr. Health 18: 249-259.
57. Pineda-Peña, E. A., J. M. Jiménez-Andrade, G. Castañeda-Hernández and A. E. Chávez-Piña. 2012. Docosahexaenoic acid, an omega-3 polyunsaturated acid protects against indomethacin-induced gastric injury. Eur. J. Pharmacol. 697: 139-143.
58. Papadakis, K. A., and S. R. Targan. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 51: 289-298.
59. Brown, S. J., and L. Mayer. 2007. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102: 2058-2069.
60. Danese, S., M. Sans, C. de la Motte, C. Graziani, G. West, M. H. Phillips, R. Pola, S. Rutella, J. Willis, A. Gasbarrini, and C. Fiocchi. 2006. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130: 2060-2073.
61. MacDermott, R. P., J. A. Green, and C. C. Ashley. 2008. What is the optimal therapy for severe ulcerative colitis? Inflamm. Bowel Dis. 14(Suppl. 2): S228-S231.
62. Buanne, P., E. Di Carlo, L. Caputi, L. Brandolini, M. Mosca, F. Cattani, L. Pellegrini, L. Biordi, G. Coletti, C. Sorrentino, et al. 2007. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J. Leukoc. Biol. 82: 1239-1246.
63. Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417-429.
64. Danese, S., S. Semeraro, M. Marini, I. Roberto, A. Armuzzi, A. Papa, and A. Gasbarrini. 2005. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig. Liver Dis. 37: 811-818.
65. Haas-Stapleton, E. J., Y. Lu, S. Hong, M. Arita, S. Favoreto, S. Nigam, C. N. Serhan, and N. Agabian. 2007. Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE 2: e1316.
66. Scheel-Toellner, D., K. Wang, R. Craddock, P. R. Webb, H. M. McGettrick, L. K. Assi, N. Parkes, L. E. Clough, E. Gulbins, M. Salmon, and J. M. Lord. 2004. Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood 104: 2557-2564.
67. Takamiya, R., K. Fukunaga, M. Arita, J. Miyata, H. Seki, N. Minematsu, M. Suematsu, and K. Asano. 2012. Resolvin E1 maintains macrophage function under cigarette smoke-induced oxidative stress. FEBS Open Bio. 2: 328-333.
68. Titos, E., B. Rius, A. González-Périz, C. López-Vicario, E. Morán-Salvador, M. Martínez-Clemente, V. Arroyo, and J. Clària. 2011. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 187: 5408-5418.
69. Morgan, M. J., and Z. G. Liu. 2011. Crosstalk of reactive oxygen species and NF-kB signaling. Cell Res. 21: 103-115.
70. Beinke, S., and S. C. Ley. 2004. Functions of NF-kB1 and NF-kB2 in immune cell biology. Biochem. J. 382: 393-409.
71. Novak, T. E., T. A. Babcock, D. H. Jho, W. S. Helton, and N. J. Espat. 2003. NFkB inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-A transcription. Am. J. Physiol. Lung Cell. Mol. Physiol. 284: L84-L89.
72. Singer, P., H. Shapiro, M. Theilla, R. Anbar, J. Singer, and J. Cohen. 2008. Antiinflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 34: 1580-1592.
73. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27: 451-483.
74. Martinez, F. O., A. Sica, A. Mantovani, and M. Locati. 2008. Macrophage activation and polarization. Front. Biosci. 13: 453-461.
75. Stout, R. D. 2010. Editorial: macrophage functional phenotypes: no alternatives in dermal wound healing? J. Leukoc. Biol. 87: 19-21.